Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Post-marketing, Prospective, Multicenter Study to Investigate the Safety and Effectiveness of Cinnomer® (Glatiramer-Acetate) in Multiple Sclerosis (MS) Treatment in Iran

NCT04928313 is registered in ClinicalTrials.gov with Cinnagen as lead sponsor.

NCT NCT04928313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04928313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Post-marketing, Prospective, Multicenter Study to Investigate the Safety and Effectiveness of Cinnomer® (Glatiramer-Acetate) in Multiple Sclerosis (MS) Treatment in Iran
Lead sponsor
Cinnagen
Phase
Observational
Overall status
Completed
Start date
April 12, 2015
Completion date
February 17, 2020
Enrollment
368 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis